These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39073766)

  • 1. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa.
    González-Pinto L; Alonso-García I; Blanco-Martín T; Camacho-Zamora P; Fraile-Ribot PA; Outeda-García M; Lasarte-Monterrubio C; Guijarro-Sánchez P; Maceiras R; Moya B; Juan C; Vázquez-Ucha JC; Beceiro A; Oliver A; Bou G; Arca-Suárez J
    J Antimicrob Chemother; 2024 Oct; 79(10):2591-2597. PubMed ID: 39073766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
    Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
    Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
    J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.
    Blanco-Martín T; López-Hernández I; Aracil B; González-Pinto L; Aja-Macaya P; Alonso-García I; Rodríguez-Pallares S; Sánchez-Peña L; Outeda-García M; Pérez-Vázquez M; Vázquez-Ucha JC; Beceiro A; Pascual Á; Bou G; López-Cerero L; Oteo-Iglesias J; Arca-Suárez J;
    Antimicrob Agents Chemother; 2024 Oct; ():e0092424. PubMed ID: 39382274
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Santerre Henriksen A; Jeannot K; Oliver A; Perry JD; Pletz MW; Stefani S; Morrissey I; Longshaw C;
    Microbiol Spectr; 2024 Apr; 12(4):e0383623. PubMed ID: 38483164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to ceftazidime-avibactam and other new β-lactams in
    Valzano F; La Bella G; Lopizzo T; Curci A; Lupo L; Morelli E; Mosca A; Marangi M; Melfitano R; Rollo T; De Nittis R; Arena F
    Microbiol Spectr; 2024 Aug; 12(8):e0426623. PubMed ID: 38934607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARGONAUT-III and -V: susceptibility of carbapenem-resistant
    Jacobs MR; Abdelhamed AM; Good CE; Mack AR; Bethel CR; Marshall S; Hujer AM; Hujer KM; Patel R; van Duin D; Fowler VG; Rhoads DD; Six DA; Moeck G; Uehara T; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0075124. PubMed ID: 39133021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
    Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
    Le Terrier C; Nordmann P; Freret C; Seigneur M; Poirel L
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0033923. PubMed ID: 37255469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of
    Le Terrier C; Nordmann P; Buchs C; Poirel L
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0154823. PubMed ID: 38415988
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Castanheira M; Kimbrough JH; Lindley J; Doyle TB; Ewald JM; Sader HS
    Antimicrob Agents Chemother; 2024 May; 68(5):e0136323. PubMed ID: 38526050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
    Alonso-García I; Vázquez-Ucha JC; Lasarte-Monterrubio C; González-Mayo E; Lada-Salvador P; Vela-Fernández R; Aja-Macaya P; Guijarro-Sánchez P; Rumbo-Feal S; Muíño-Andrade M; Fernández-González A; Martínez-Guitián M; Beceiro A; Rodríguez-Iglesias M; Oliver A; Arca-Suárez J; Galán-Sánchez F; Bou G
    J Antimicrob Chemother; 2023 May; 78(5):1195-1200. PubMed ID: 36918743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
    Le Terrier C; Nordmann P; Poirel L
    J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
    Buyukyanbolu E; Genc L; Cyr EA; Karakus M; Comert F; Otlu B; Aktas E; Nicolau DP
    Eur J Clin Microbiol Infect Dis; 2024 Sep; 43(9):1787-1794. PubMed ID: 38995343
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
    Poirel L; Ortiz de la Rosa JM; Sadek M; Nordmann P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0003922. PubMed ID: 35315685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.